Abstract Objectives Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our
hospital and worldwide, raising the necessity of finding effective therapies. We aimed to …

Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter
baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In …

Background Infections sustained by multidrug-resistant (MDR) and pan-resistant
Acinetobacter baumannii have become a challenging problem in Intensive Care Units …

Abstract Objectives Multidrug-resistant Acinetobacter baumannii (MRAB) is an increasing
problem in UK hospitals, with many strains now resistant to all available antibiotics except …

Because of its remarkable ability to acquire antibiotic resistance and to survive in
nosocomial environments, Acinetobacter baumannii has become a significant nosocomial …

Objectives: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet,
published clinical experience with tigecycline use outside clinical trials is lacking. We …

Sir, Acinetobacter baumannii is a significant nosocomial pathogen, in particular in ICU
patients. Their multidrug resistance, propensity for clonal spread and involvement in hospital …

Tigecycline has an extended spectrum of in vitro antimicrobial activities, including that
against multidrug-resistant Acinetobacter. After identifying bloodstream isolates of …

A 53‐year‐old woman experienced a multidrug‐resistant (MDR) Acinetobacter baumannii
urinary tract infection 5 months after undergoing kidney and liver transplantation. The …

Objectives New antibacterial agents are required for the treatment of infections caused by
multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective …